Humira®

Active substance

Adalimumab

Holder

AbbVie SA/NV

Status

Closed

Indication

Treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies

Public documents

Approbation

Information for the patient

Infromed consent for children under 12 years old

Informed consent for patients older than 12 years

Last update

17/07/2017

Last updated on 13/02/2024